NCT07169656 Observation Study on Reducing the Risk of Liver Cancer Associated With Hepatitis B (Zhiyuan) Project.
| NCT ID | NCT07169656 |
| Status | Recruiting |
| Phase | — |
| Sponsor | The First Affiliated Hospital of Zhengzhou University |
| Condition | Chronic Hepatitis b |
| Study Type | OBSERVATIONAL |
| Enrollment | 15,000 participants |
| Start Date | 2024-06-03 |
| Primary Completion | 2032-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 15,000 participants in total. It began in 2024-06-03 with a primary completion date of 2032-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study is a multicenter, prospective, observational real-world study designed to investigate and analyze the current treatment patterns of chronic hepatitis B (CHB) across 200 hospitals in China. By comparing patient outcomes under different therapeutic regimens, it aims to provide high-quality evidence-based medical data to optimize CHB treatment strategies and follow-up protocols, ultimately contributing to the advancement of a functional cure for chronic hepatitis B.
Eligibility Criteria
Inclusion Criteria: * 1.Chronic HBV infection (HBsAg-positive for ≥6 months); 2.Age ≥18 years; 3.Patients who, based on real-world clinical practice needs, are planned or currently receiving treatment with:Entecavir (ETV),Tenofovir disoproxil fumarate (TDF),Tenofovir alafenamide fumarate (TAF),Tenofovir amibufenamide (TMF) OR Pegylated interferon α-2b-naïve patients OR Patients re-initiating pegylated interferon α-2b therapy; 4.Written informed consent obtained from the patient. Exclusion Criteria: * 1.Severe hepatic dysfunction or decompensated cirrhosis; 2.Concurrent participation in other clinical trials; 3.Hepatocellular carcinoma (HCC).
Contact & Investigator
Hongxia Liang
PRINCIPAL INVESTIGATOR
The First Affiliated Hospital of Zhengzhou University
Frequently Asked Questions
Who can join the NCT07169656 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Chronic Hepatitis b. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07169656 currently recruiting?
Yes, NCT07169656 is actively recruiting participants. Contact the research team at hxliang@zzu.edu.cn for enrollment information.
Where is the NCT07169656 trial being conducted?
This trial is being conducted at Anyang, China, Anyang, China, Anyang, China, Anyang, China and 11 additional locations.
Who is sponsoring the NCT07169656 clinical trial?
NCT07169656 is sponsored by The First Affiliated Hospital of Zhengzhou University. The principal investigator is Hongxia Liang at The First Affiliated Hospital of Zhengzhou University. The trial plans to enroll 15,000 participants.